Steven Cohen Belite Bio, Inc Call Options Transaction History
Point72 Asset Management, L.P.
- $39.3 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding BLTE
# of Institutions
12Shares Held
58.3KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA16.7KShares$819,1630.0% of portfolio
-
Marshall Wace, LLP London, X010.6KShares$520,0970.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$329,2380.0% of portfolio
-
Morgan Stanley New York, NY6.09KShares$299,2620.0% of portfolio
-
Cubist Systematic Strategies, LLC Stamford, CT4.79KShares$235,2820.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.22B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...